Key facts
- This page summarizes Maykin Ho's Form 4 filing for Neumora Therapeutics, Inc. (NMRA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Jun 2024, 16:18.
Maykin Ho - 13 Jun 2024 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)
- Reporting relationship
- Director
- Issuer ticker
- NMRA
- Reported as of
- 13 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2024, 16:18:00 UTC
- Prior SEC filing
- 06 Jun 2024
- Next SEC filing
- 24 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joshua Pinto, as Attorney-in-Fact for Maykin Ho
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Maykin Ho filed Form 4 for Neumora Therapeutics, Inc. (NMRA) on 14 Jun 2024.
Change
- Previous filing in this sequence was filed on 06 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NMRA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +20,100
- Change %
- Price
- $0.000000
- Shares after
- 20,100
- Date
- 13 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NMRA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +28,571
- Change %
- Price
- $0.000000
- Shares after
- 28,571
- Date
- 13 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 28,571
- Exercise price
- $9.95
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.
Footnote F2
100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.